Molecular Imaging of Steroid Receptors in Breast Cancer

被引：1

作者：

Keigley, Quinton J. ^{[1
]}

Fowler, Amy M. ^{[1
,2
,3
]}

O'Brien, Sophia R. ^{[4
]}

Dehdashti, Farrokh ^{[5
]}

机构：

[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI USA

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI USA

[4] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA USA

[5] Washington Univ, Edward Mallinckrodt Inst Radiol, Alvin J Siteman Canc Ctr, Div Nucl Med,Sch Med, 510 S Kingshighway Blvd, St. Louis, MO 63110 USA

来源：

CANCER JOURNAL | 2024年 / 30卷 / 03期

关键词：

Estrogen receptor; progesterone receptor; androgen receptor; positron emission tomography; breast cancer; POSITRON-EMISSION-TOMOGRAPHY; LIGAND-BINDING ASSAY; PHASE-II TRIAL; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTORS; ENDOCRINE THERAPY; HORMONE RECEPTORS; F-18-FES PET; FES-PET; F-18-FLUOROESTRADIOL PET/CT;

D O I：

10.1097/PPO.0000000000000715

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Steroid receptors regulate gene expression for many important physiologic functions and pathologic processes. Receptors for estrogen, progesterone, and androgen have been extensively studied in breast cancer, and their expression provides prognostic information as well as targets for therapy. Noninvasive imaging utilizing positron emission tomography and radiolabeled ligands targeting these receptors can provide valuable insight into predicting treatment efficacy, staging whole-body disease burden, and identifying heterogeneity in receptor expression across different metastatic sites. This review provides an overview of steroid receptor imaging with a focus on breast cancer and radioligands for estrogen, progesterone, and androgen receptors.

引用

页码：142 / 152

页数：11

共 167 条

[81] Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate [J].

Lee, Oukseub ;

Sullivan, Megan E. ;

Xu, Yanfei ;

Rogers, Chiara ;

Muzzio, Miguel ;

Helenowski, Irene ;

Shidfar, Ali ;

Zeng, Zexian ;

Singhal, Hari ;

Jovanovic, Borko ;

Hansen, Nora ;

Bethke, Kevin P. ;

Gann, Peter H. ;

Gradishar, William ;

Kim, J. Julie ;

Clare, Susan E. ;

Khan, Seema A. .

CLINICAL CANCER RESEARCH, 2020, 26 (01) :25-34

[82] Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer [J].

Leo, Javier ;

Dondossola, Eleonora ;

Basham, Kaitlin J. ;

Wilson, Nathaniel R. ;

Alhalabi, Omar ;

Gao, Jianjun ;

Kurnit, Katherine C. ;

White, Michael G. ;

McQuade, Jennifer L. ;

Westin, Shannon N. ;

Wellberg, Elizabeth A. ;

Frigo, Daniel E. .

ENDOCRINOLOGY, 2023, 164 (06)

[83] Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998 [J].

Li, CI ;

Daling, JR ;

Malone, KE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :28-34

[84] Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy [J].

Lin, Frank I. ;

Gonzalez, E. M. ;

Kummar, S. ;

Do, K. ;

Shih, J. ;

Adler, S. ;

Kurdziel, K. A. ;

Ton, A. ;

Turkbey, B. ;

Jacobs, P. M. ;

Bhattacharyya, S. ;

Chen, A. P. ;

Collins, J. M. ;

Doroshow, J. H. ;

Choyke, P. L. ;

Lindenberg, M. L. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (03) :500-508

[85] Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer [J].

Linden, Hannah M. ;

Stekhova, Svetlana A. ;

Link, Jeanne M. ;

Gralow, Julie R. ;

Livingston, Robert B. ;

Ellis, Georgiana K. ;

Petra, Philip H. ;

Peterson, Lanell M. ;

Schubert, Erin K. ;

Dunnwald, Lisa K. ;

Krohn, Kenneth A. ;

Mankoff, David A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2793-2799

[86] Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer [J].

Linden, Hannah M. ;

Kurland, Brenda F. ;

Peterson, Lanell M. ;

Schubert, Erin K. ;

Gralow, Julie R. ;

Specht, Jennifer M. ;

Ellis, Georgiana K. ;

Lawton, Thomas J. ;

Livingston, Robert B. ;

Petra, Philip H. ;

Link, Jeanne M. ;

Krohn, Kenneth A. ;

Mankoff, David A. .

CLINICAL CANCER RESEARCH, 2011, 17 (14) :4799-4805

[87] 18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment [J].

Liu, Cheng ;

Ma, Guang ;

Zhang, Jiangang ;

Cheng, Jingyi ;

Yang, Zhongyi ;

Song, Shaoli .

ANNALS OF NUCLEAR MEDICINE, 2023, 37 (12) :675-684

[88] Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment [J].

Liu, Cheng ;

Hu, Shihui ;

Xu, Xiaoping ;

Zhang, Yongping ;

Wang, Biyun ;

Song, Shaoli ;

Yang, Zhongyi .

BREAST CANCER RESEARCH, 2022, 24 (01)

[89] Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2-Metastatic Breast Cancer [J].

Liu, Cheng ;

Xu, Xiaoping ;

Yuan, Huiyu ;

Zhang, Yongping ;

Zhang, Yingjian ;

Song, Shaoli ;

Yang, Zhongyi .

FRONTIERS IN ONCOLOGY, 2020, 10

[90] 18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT [J].

Liu, Cheng ;

Gong, Chengcheng ;

Liu, Shuai ;

Zhang, Yingjian ;

Zhang, Yongping ;

Xu, Xiaoping ;

Yuan, Huiyu ;

Wang, Biyun ;

Yang, Zhongyi .

ONCOLOGIST, 2019, 24 (12) :E1277-E1285

← 4 5 6 7 8 9 10 11 12 13 →